“We are very happy to report this progress in the ADVENT-AML clinical trial,” said Jason B Litten MD,
Chief Medical Officer of Chimeric Therapeutics. “The novel combination of CHM 0201 with the standard
of care in AML treatment has the potential to transform frontline therapy and enhance outcomes for
AML patients.”
And that alone would justify an EV of USD 500m if recent Pharma deals a guide to go by.
Current EV, less than AUD 10m
GLTA
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-2
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.002(11.1%) |
Mkt cap ! $17.25M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.1¢ | 1.9¢ | $56.44K | 2.801M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1655923 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 1520755 | 2 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CHM (ASX) Chart |